Main Article Content
Efficacité et tolérance de l’association artéméther luméfantrine dans le traitement du paludisme simple à <i>Plasmodium falciparum</i> au Niger
Abstract
Background: Malaria, with its width, its gravity and its economic and social consequences remains a major public health problem in tropical countries like Niger. These consequences come to be added the simultaneous or cross résistance of P.falciparum to currents drugs. The National Malaria Programme of Niger adopted artemether-lumefantrine (COARTEM®) in treatment of uncomplicated malaria in 2005. We evaluated the efficacy and safety of artémether-luméfantrine in the treatment of children less than 5 years at Gaya, Tessaoua and Agades, three sentinels’ sites of Niger.
Objectives: The main objective of the study is to evaluate the efficacy and the safety of COARTEM® in the treatment of uncomplicated P.falciparum malaria in Niger.
Methodology: It is a multicentric, prospective, descriptive and open study with only one arm to evaluate the efficacy and safety of artemether-lumefantrine in children less than 5 years suffering from uncomplicated malaria in Niger. OMS/2003 protocol was used.
Results: 389 children were consulted and 199 children were followed for 28 days. 81 children are from Gaya, 70 from Tessaoua and 48 from Agades. After PCR, the clinical and parasitological adequate response (CPAR) of children less than 5 years is 92%. The CPAR is 96.3% at Tessaoua, 94.1% at Agades and 89.6% at Gaya. The difference of response between the three sentinels sites is not significant (p>005). Before PCR, the clinical and parasitological adequate response was 88.8%. The COARTEM® is well tolerated. No undesirable effect was observed during the study.
Conclusion: COARTEM® is an effective drug, which reduces significantly parasitic and clinical symptoms of malaria. It can be prescribed in treatment of uncomplicated malaria as public health ministry of Niger recommends. COARTEM® is also safety and well tolerated by the patients.
Keywords: Efficacy, Safety, Artemether-lumefantrine, P. falciparum, Niger
J. Rech. Sci. Univ. Lomé (Togo), 2012, Série D, 14(1) : 79-84
Objectives: The main objective of the study is to evaluate the efficacy and the safety of COARTEM® in the treatment of uncomplicated P.falciparum malaria in Niger.
Methodology: It is a multicentric, prospective, descriptive and open study with only one arm to evaluate the efficacy and safety of artemether-lumefantrine in children less than 5 years suffering from uncomplicated malaria in Niger. OMS/2003 protocol was used.
Results: 389 children were consulted and 199 children were followed for 28 days. 81 children are from Gaya, 70 from Tessaoua and 48 from Agades. After PCR, the clinical and parasitological adequate response (CPAR) of children less than 5 years is 92%. The CPAR is 96.3% at Tessaoua, 94.1% at Agades and 89.6% at Gaya. The difference of response between the three sentinels sites is not significant (p>005). Before PCR, the clinical and parasitological adequate response was 88.8%. The COARTEM® is well tolerated. No undesirable effect was observed during the study.
Conclusion: COARTEM® is an effective drug, which reduces significantly parasitic and clinical symptoms of malaria. It can be prescribed in treatment of uncomplicated malaria as public health ministry of Niger recommends. COARTEM® is also safety and well tolerated by the patients.
Keywords: Efficacy, Safety, Artemether-lumefantrine, P. falciparum, Niger
J. Rech. Sci. Univ. Lomé (Togo), 2012, Série D, 14(1) : 79-84
